PL2542584T3 - Sposoby leczenia nowotworu trzustki - Google Patents

Sposoby leczenia nowotworu trzustki

Info

Publication number: PL2542584T3
Authority: PL; Poland
Prior art keywords: methods; pancreatic cancer; treating pancreatic; treating; cancer
Prior art date: 2010-01-08

Application number

PL11700115T

Other languages

English (en)

Inventor

Leïla HOUHOU

Dominique Joubert

Frédéric HOLLANDE

Original Assignee

Progastrine Et Cancers S.À R.L.

Institut National De La Sante Et De La Recherche Medicale (Inserm)

Centre National De La Recherche Scientifique (Cnrs)

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-01-08

Filing date

2011-01-07

Publication date

2018-04-30

2011-01-07 Application filed by Progastrine Et Cancers S.À R.L., Institut National De La Sante Et De La Recherche Medicale (Inserm), Centre National De La Recherche Scientifique (Cnrs) filed Critical Progastrine Et Cancers S.À R.L.

2018-04-30 Publication of PL2542584T3 publication Critical patent/PL2542584T3/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/595—Gastrins; Cholecystokinins [CCK]
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Cell Biology (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Microbiology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Endocrinology (AREA)
Pathology (AREA)
Physics & Mathematics (AREA)
Biotechnology (AREA)
Hospice & Palliative Care (AREA)
Analytical Chemistry (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Epidemiology (AREA)
Mycology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

PL11700115T 2010-01-08 2011-01-07 Sposoby leczenia nowotworu trzustki PL2542584T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US29361210P	2010-01-08	2010-01-08
EP11700115.6A EP2542584B8 (en)	2010-01-08	2011-01-07	Methods for treating pancreatic cancer
PCT/EP2011/000049 WO2011083091A2 (en)	2010-01-08	2011-01-07	Methods for treating pancreatic cancer

Publications (1)

Publication Number	Publication Date
PL2542584T3 true PL2542584T3 (pl)	2018-04-30

Family

ID=43607948

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL11700115T PL2542584T3 (pl)	2010-01-08	2011-01-07	Sposoby leczenia nowotworu trzustki
PL11700068T PL2542583T3 (pl)	2010-01-08	2011-01-07	Sposoby leczenia nowotworu piersi

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL11700068T PL2542583T3 (pl)	2010-01-08	2011-01-07	Sposoby leczenia nowotworu piersi

Country Status (15)

Country	Link
US (2)	US8900588B2 (pl)
EP (2)	EP2542584B8 (pl)
JP (2)	JP5572718B2 (pl)
KR (2)	KR101468397B1 (pl)
CN (2)	CN102933603B (pl)
AU (2)	AU2011204653B2 (pl)
BR (2)	BR112012016820A2 (pl)
CA (2)	CA2786435C (pl)
EA (2)	EA025329B1 (pl)
ES (2)	ES2657246T3 (pl)
NZ (2)	NZ601588A (pl)
PL (2)	PL2542584T3 (pl)
SG (2)	SG182331A1 (pl)
WO (2)	WO2011083090A2 (pl)
ZA (2)	ZA201205004B (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8136651B2 (en) *	2007-12-14	2012-03-20	The Procter & Gamble Company	Method and apparatus for orienting articles
WO2008076454A1 (en)	2006-12-19	2008-06-26	The Board Of Regents Of The University Of Texas System	Immunogenic compositions comprising progastrin and uses thereof
NZ606195A (en) *	2010-07-26	2015-02-27	Servier Lab	Methods and compositions for liver cancer therapy
US11078286B2 (en)	2015-09-20	2021-08-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Monoclonal antibodies specific for fibroblast growth factor receptor 4 (FGFR4) and methods of their use
MX2018008175A (es) *	2015-12-31	2019-02-20	Syncerus S A R L	Composiciones y metodos para evaluar el riesgo de ocurrencia de cancer.
EP3954998A1 (en) *	2015-12-31	2022-02-16	Progastrine et Cancers S.à r.l.	Compositions and methods for detecting and treating gastric cancer
PL3397964T3 (pl)	2015-12-31	2022-02-07	Progastrine Et Cancers S.À R.L.	Kompozycje i sposoby do wykrywania i leczenia raka jajnika
EP3397967B1 (en) *	2015-12-31	2020-12-30	Progastrine et Cancers S.à r.l.	Compositions and methods for detecting and treating esophageal cancer
CN110402143B (zh) *	2017-01-06	2022-11-22	雷莫内克斯生物制药有限公司	预防或治疗转移性卵巢癌、子宫内膜癌或乳腺癌的组合物
ES2926532T3 (es) *	2017-03-30	2022-10-26	Progastrine Et Cancers S A R L	Composiciones y métodos para tratar el cáncer de pulmón
US11644468B2 (en)	2017-03-30	2023-05-09	Progastrine et Cancers S.à r.L	Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule
WO2019055776A2 (en)	2017-09-14	2019-03-21	Rosser Charles	COMPOSITIONS AND METHODS FOR TREATING DISEASES INVOLVING CXCL1 FUNCTION
US11046758B2 (en) *	2017-12-05	2021-06-29	Progastrine Et Cancers S.À R.L.	Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
CN112004560A (zh)	2017-12-08	2020-11-27	Ecs生物识别***有限公司	癌症诊断中的放射性标记的前胃液素
TW201940881A (zh)	2018-01-26	2019-10-16	瑞士商Ｅｃｓ前胃泌激素公司	在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
SG11202008271QA (en)	2018-02-27	2020-09-29	Ecs Progastrin Sa	Progastrin as a biomarker for immunotherapy
CN111954681B (zh)	2018-03-13	2022-12-06	东莞凡恩世生物医药有限公司	抗叶酸受体1抗体及其用途
CN108864255B (zh) *	2018-06-21	2022-01-04	天津医科大学肿瘤医院	一种乳腺癌干细胞特异性结合多肽及其在制备治疗乳腺癌药物中的应用
JP2022517865A (ja)	2019-01-28	2022-03-10	ジェイロッサ― チャールズ	Ｃｘｃｌ１機能に関与する疾患の治療のための組成物および方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en)	1982-11-18	1985-04-09	Chiron Corporation	Adenovirus promoter system
US5168062A (en)	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en)	1985-12-18	1990-11-06	Ciba-Geigy Corporation	Deoxyribonucleic acid segment from a virus
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
DE69233482T2 (de)	1991-05-17	2006-01-12	Merck & Co., Inc.	Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
US5922845A (en) *	1996-07-11	1999-07-13	Medarex, Inc.	Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
DE69827621T9 (de) *	1997-05-12	2007-06-06	Aphton Corp., Woodland	Immunogene zusammensetzungen gegen den cck-b-gastrin-rezeptor und verfahren zur behandlung von tumoren
AU2001241710B2 (en)	2000-02-25	2005-07-21	The Regents Of The University Of California	Membrane estrogen receptor-directed therapy in breast cancer
FR2846426B1 (fr)	2002-10-28	2004-12-10	Bio Merieux	Procede de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
CN101048659B (zh) *	2004-09-22	2013-03-13	受体生物技术公司	抗前胃泌素单克隆抗体
AU2007252986B2 (en)	2006-05-22	2013-03-21	Centre National De La Recherche Scientifique - Cnrs-	Progastrin inhibitors in the treatment of colon cancer
EP2062597A4 (en)	2006-09-15	2010-03-03	Univ Tokai	PREVENTIVE OR CLEANING AGENT FOR ER-NEGATIVE AND HER2-NEGATIVE MAMMARY CARCINOMA AND INVESTIGATION METHOD THEREFOR
US20100092476A1 (en)	2006-11-17	2010-04-15	Hanash Samir M	Pancreatic cancer biomarkers
WO2008076454A1 (en)	2006-12-19	2008-06-26	The Board Of Regents Of The University Of Texas System	Immunogenic compositions comprising progastrin and uses thereof
EP2205077A4 (en)	2007-09-24	2010-12-29	Tragara Pharmaceuticals Inc	THERAPIES FOR THE TREATMENT OF CANCER BASED ON COMBINATIONS OF COX-2 INHIBITORS AND ANTI-HER2 (ERBB2) ANTIBODIES OR COMBINATIONS OF COX-2 INHIBITORS AND HER2 (ERBB2) RECEPTOR TYROSINE KINASE INHIBITORS
EP3421493B1 (en) *	2009-10-16	2024-01-17	Progastrine et Cancers S.à r.l.	Monoclonal antibodies to progastrin and their uses

2011
- 2011-01-04 US US12/984,509 patent/US8900588B2/en not_active Expired - Fee Related
- 2011-01-04 US US12/984,522 patent/US9487582B2/en active Active
- 2011-01-07 SG SG2012049136A patent/SG182331A1/en unknown
- 2011-01-07 JP JP2012547494A patent/JP5572718B2/ja not_active Expired - Fee Related
- 2011-01-07 EA EA201200999A patent/EA025329B1/ru not_active IP Right Cessation
- 2011-01-07 KR KR1020127020871A patent/KR101468397B1/ko active IP Right Grant
- 2011-01-07 JP JP2012547495A patent/JP6134141B2/ja not_active Expired - Fee Related
- 2011-01-07 BR BR112012016820A patent/BR112012016820A2/pt not_active IP Right Cessation
- 2011-01-07 NZ NZ601588A patent/NZ601588A/en not_active IP Right Cessation
- 2011-01-07 CN CN201180013036.8A patent/CN102933603B/zh not_active Expired - Fee Related
- 2011-01-07 AU AU2011204653A patent/AU2011204653B2/en not_active Ceased
- 2011-01-07 EA EA201200998A patent/EA023722B1/ru not_active IP Right Cessation
- 2011-01-07 CN CN201180013038.7A patent/CN102892784B/zh not_active Expired - Fee Related
- 2011-01-07 PL PL11700115T patent/PL2542584T3/pl unknown
- 2011-01-07 SG SG2012049177A patent/SG182334A1/en unknown
- 2011-01-07 CA CA2786435A patent/CA2786435C/en not_active Expired - Fee Related
- 2011-01-07 EP EP11700115.6A patent/EP2542584B8/en active Active
- 2011-01-07 WO PCT/EP2011/000048 patent/WO2011083090A2/en active Application Filing
- 2011-01-07 PL PL11700068T patent/PL2542583T3/pl unknown
- 2011-01-07 CA CA2786479A patent/CA2786479C/en not_active Expired - Fee Related
- 2011-01-07 ES ES11700115.6T patent/ES2657246T3/es active Active
- 2011-01-07 ES ES11700068.7T patent/ES2657245T3/es active Active
- 2011-01-07 AU AU2011204654A patent/AU2011204654B2/en not_active Ceased
- 2011-01-07 EP EP11700068.7A patent/EP2542583B8/en active Active
- 2011-01-07 BR BR112012016742A patent/BR112012016742A2/pt not_active Application Discontinuation
- 2011-01-07 WO PCT/EP2011/000049 patent/WO2011083091A2/en active Application Filing
- 2011-01-07 KR KR1020127020835A patent/KR101438362B1/ko active IP Right Grant
- 2011-01-07 NZ NZ601591A patent/NZ601591A/en not_active IP Right Cessation
2012
- 2012-07-04 ZA ZA2012/05004A patent/ZA201205004B/en unknown
- 2012-07-04 ZA ZA2012/05003A patent/ZA201205003B/en unknown

Also Published As

Publication number	Publication date
WO2011083091A2 (en)	2011-07-14
ZA201205004B (en)	2013-09-25
AU2011204653A1 (en)	2012-07-26
CN102933603A (zh)	2013-02-13
JP2013516439A (ja)	2013-05-13
US9487582B2 (en)	2016-11-08
ZA201205003B (en)	2013-09-25
KR20130028050A (ko)	2013-03-18
SG182331A1 (en)	2012-08-30
US8900588B2 (en)	2014-12-02
EP2542584A2 (en)	2013-01-09
KR101468397B1 (ko)	2014-12-04
US20110177062A1 (en)	2011-07-21
EP2542584B1 (en)	2017-10-25
CA2786435A1 (en)	2011-07-14
NZ601588A (en)	2014-07-25
AU2011204653B2 (en)	2014-04-10
CA2786479C (en)	2016-03-15
EA201200999A1 (ru)	2013-02-28
CN102892784B (zh)	2016-06-22
JP2013516438A (ja)	2013-05-13
EP2542583B1 (en)	2017-10-25
SG182334A1 (en)	2012-08-30
EP2542584B8 (en)	2017-12-13
CA2786479A1 (en)	2011-07-14
WO2011083090A3 (en)	2011-10-06
EP2542583A2 (en)	2013-01-09
AU2011204654A1 (en)	2012-07-26
CN102933603B (zh)	2016-01-20
ES2657245T3 (es)	2018-03-02
WO2011083090A2 (en)	2011-07-14
ES2657246T3 (es)	2018-03-02
EA025329B1 (ru)	2016-12-30
WO2011083091A3 (en)	2011-09-09
CN102892784A (zh)	2013-01-23
US20110171213A1 (en)	2011-07-14
JP6134141B2 (ja)	2017-05-24
KR20120135401A (ko)	2012-12-13
PL2542583T3 (pl)	2018-04-30
EA201200998A1 (ru)	2013-02-28
EA023722B1 (ru)	2016-07-29
BR112012016742A2 (pt)	2018-05-15
KR101438362B1 (ko)	2014-09-05
EP2542583B8 (en)	2017-12-13
CA2786435C (en)	2017-01-17
JP5572718B2 (ja)	2014-08-13
NZ601591A (en)	2015-01-30
BR112012016820A2 (pt)	2023-11-28
AU2011204654B2 (en)	2014-04-10
WO2011083091A8 (en)	2012-08-09

Publication	Publication Date	Title
IL276362A (en)	2020-08-31	Cancer treatment methods
HK1252832A1 (zh)	2019-06-06	用於治療結腸直腸癌的方法
ZA201205004B (en)	2013-09-25	Methods for treating pancreatic cancer
ZA201208821B (en)	2014-01-29	Methods of treatment of pancreatic cancer
EP2558109A4 (en)	2014-09-24	METHOD FOR TREATING HARD TUMORS
IL227429A0 (en)	2013-09-30	The components and methods of cancer treatment
EP2755482A4 (en)	2015-03-25	COMPOSITIONS AND METHODS OF TREATING CANCER
EP2643001A4 (en)	2014-02-19	METHOD OF TREATING CANCER
EP2635286A4 (en)	2014-11-12	METHOD FOR THE TREATMENT OF CANCER
EP2771341A4 (en)	2015-09-23	NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
EP2498094A4 (en)	2012-12-05	METHOD OF DETECTING PANCREATIC CANCER
HK1189272A1 (zh)	2014-05-30	治療癌症的方法
IL228644A0 (en)	2013-12-31	Cancer treatment methods
HRP20160851T1 (hr)	2016-09-23	Prediktori za liječenje karcinoma
EP2640390A4 (en)	2014-08-06	METHODS OF TREATING CANCER
IL229231A0 (en)	2014-01-30	Preparations and methods for the treatment of cancer
HK1188566A1 (zh)	2014-05-09	治療癌症的組合物和方法
EP2560648A4 (en)	2013-10-02	METHOD OF TREATING PANCREATIC CANCER
PT2509599E (pt)	2014-10-15	Processo para o tratamento de cancro pancreático
EP2538944A4 (en)	2013-08-28	METHOD FOR TREATING BRAIN TUMORS
EP2593100A4 (en)	2014-01-01	METHOD OF TREATING REFRACTORY CANCER
GB201220901D0 (en)	2013-01-02	CD44v6-derived peptides for treating pancreatic cancer
EP2707011A4 (en)	2014-11-19	METHOD FOR THE TREATMENT OF PROSTATE CANCER